Company Description
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024.
The company was incorporated in 2005 and is headquartered in San Mateo, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Feb 14, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Vincent Angotti |
Contact Details
Address: 1850 Gateway Drive, Suite 175 San Mateo, California 94404 United States | |
| Phone | 650 216 3500 |
| Website | talphera.com |
Stock Details
| Ticker Symbol | TLPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001427925 |
| ISIN Number | US00444T2096 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vincent J. Angotti | Chief Executive Officer and Director |
| Raffi Mark Asadorian | Chief Financial Officer |
| Anil N. Dasu | Chief Engineering Officer |
| Dr. Shakil Aslam M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 1, 2024 | 8-K | Current Report |
| Aug 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Jun 24, 2024 | 8-K | Current Report |
| May 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |